Why I’m considering FTSE 100 income and growth champion AstraZeneca plc

AstraZeneca plc (LSE: AZN) looks attractive to me today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) has long been considered be one of the FTSE 100’s top income stocks. However, in recent years the company’s growth has faltered as a number of its most profitable treatments have come off patent. Management has been doing everything in its power to try to revitalise growth prospects, and it looks as if these efforts are starting to pay off.

At the beginning of May, the company received approval from the US Food and Drug Administration for the sale of what it has labelled the “cornerstone” of its immune-oncology portfolio. The treatment, which is named durvalumab is expected to generate sales of more than $1bn per annum for the company, making it a so-called blockbuster treatment.

All change

Durvalumab is the first of several key drugs Astra is planning to launch over the next few years, following a strategy championed by CEO Pascal Soriot.

Unfortunately, after several years at the helm of Astra according to news reports out today, Soriot is contemplating taking up a new role as the head of Israel-based Teva Pharmaceutical Industries. Soriot has been Astra’s CEO since 2012 and saw off a takeover attempt from US peer Pfizer, which drew plenty of criticism at the time. And it looks as if he’s planning to bail out from Astra before his mission to double sales to $45bn from nearly $24.7bn in 2015 (when Soriot set this target after rejecting Pfizer’s advances) is hit.

Shares in Astra have fallen around 5% today following the news of his potential departure, a decline that seems to be entirely justified as it looks as if he has given up on the company. That being said, I believe this might be the perfect opportunity to buy into this growth story.

Slow and steady growth

Astra has come a long way from where it was when the Frenchman took over, and City analysts are expecting earnings per share to grow by 19.4% this year followed by growth of 1% next year after several years of stagnation. Through to the end of the decade, the company is expected to return to steady growth as new treatments are approved, and the impact of patent expirations become less pronounced. This year’s growth will be fuelled by sterling’s depreciation, so even though growth is expected to return it will not be organic. Over the next two to three years organic sales growth from the issue of new treatments should start to filter through.

As growth picks up, investors will be paid to wait as shares in Astra currently support a dividend yield of 4.2%, and the payout is covered 1.5 times by earnings per share.

Too expensive?

The one fundamental aspect that does make me think twice about buying a stake in Astra is the company’s current valuation. Specifically, shares in the firm currently trade at a forward P/E of 17 and while this multiple does seem suitable considering the earnings rise of 19% predicted, when growth returns to more normal levels next year, the shares will become overvalued.

Still, as a highly defensive business I believe it is worth paying a premium to buy into Astra’s growth story and with this being the case, after today’s declines, I’m taking a closer look at the business.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »